Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Elevated platelet count is a strong predictor of poor prognosis in stage I non-small cell lung cancer patients.

Ji Y, Sheng L, Du X, Qiu G, Su D.

Platelets. 2015;26(2):138-42. doi: 10.3109/09537104.2014.888547. Epub 2014 Mar 28.

PMID:
24679181
2.

Preoperative platelet count in predicting lymph node metastasis and prognosis in patients with non-small cell lung cancer.

Liu HB, Gu XL, Ma XQ, Lv TF, Wu Y, Xiao YY, Yuan DM, Li YF, Song Y.

Neoplasma. 2013;60(2):203-8.

PMID:
23259790
3.

Prognostic significance of the combined use of preoperative platelet count and serum carcinoembryonic antigen level in non-small-cell lung cancer.

Tomita M, Shimizu T, Ayabe T, Onitsuka T.

Gen Thorac Cardiovasc Surg. 2010 Nov;58(11):573-6. doi: 10.1007/s11748-010-0647-2. Epub 2010 Nov 11.

PMID:
21069496
4.

Prognostic significance of initial platelet counts and fibrinogen level in advanced non-small cell lung cancer.

Kim KH, Park TY, Lee JY, Lee SM, Yim JJ, Yoo CG, Kim YW, Han SK, Yang SC.

J Korean Med Sci. 2014 Apr;29(4):507-11. doi: 10.3346/jkms.2014.29.4.507. Epub 2014 Apr 1.

5.

Prognostic value of combination of preoperative platelet count and mean platelet volume in patients with resectable non-small cell lung cancer.

Gao L, Zhang H, Zhang B, Zhang L, Wang C.

Oncotarget. 2017 Feb 28;8(9):15632-15641. doi: 10.18632/oncotarget.14921.

6.

Prognostic impact of thrombocytosis in resectable non-small cell lung cancer.

Tomita M, Shimizu T, Hara M, Ayabe T, Onitsuka T.

Interact Cardiovasc Thorac Surg. 2008 Aug;7(4):613-5. doi: 10.1510/icvts.2007.174391. Epub 2008 May 23.

PMID:
18502783
7.

[Analysis of the factors associated with abnormal coagulation and prognosis
 in patients with non-small cell lung cancer].

Li Y, Wei S, Wang J, Hong L, Cui L, Wang C.

Zhongguo Fei Ai Za Zhi. 2014 Nov;17(11):789-96. doi: 10.3779/j.issn.1009-3419.2014.11.04. Chinese.

8.

Serum fibrinogen is an independent prognostic factor in operable nonsmall cell lung cancer.

Sheng L, Luo M, Sun X, Lin N, Mao W, Su D.

Int J Cancer. 2013 Dec 1;133(11):2720-5. doi: 10.1002/ijc.28284. Epub 2013 Jun 14.

9.

Swedish lung cancer radiation study group: the prognostic value of anaemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer.

Holgersson G, Sandelin M, Hoye E, Bergström S, Henriksson R, Ekman S, Nyman J, Helsing M, Friesland S, Holgersson M, Lundström KL, Janson C, Birath E, Mörth C, Blystad T, Ewers SB, Löden B, Bergqvist M.

Med Oncol. 2012 Dec;29(5):3176-82. doi: 10.1007/s12032-012-0247-3. Epub 2012 May 8.

PMID:
22565809
10.

Preoperative thrombocytosis is a significant unfavorable prognostic factor for patients with resectable non-small cell lung cancer.

Kim M, Chang H, Yang HC, Kim YJ, Lee CT, Lee JH, Jheon S, Kim K, Chung JH, Lee JS.

World J Surg Oncol. 2014 Feb 12;12:37. doi: 10.1186/1477-7819-12-37.

11.

Clinical significance of preoperative neutrophil-lymphocyte vs platelet-lymphocyte ratio in primary operable patients with non-small cell lung cancer.

Zhang H, Xia H, Zhang L, Zhang B, Yue D, Wang C.

Am J Surg. 2015 Sep;210(3):526-35. doi: 10.1016/j.amjsurg.2015.03.022. Epub 2015 Jun 1.

PMID:
26105800
12.

Elevation of platelet count in patients with colorectal cancer predicts tendency to metastases and poor prognosis.

Lin MS, Huang JX, Zhu J, Shen HZ.

Hepatogastroenterology. 2012 Sep;59(118):1687-90. doi: 10.5754/hge12277.

PMID:
22591645
13.

[Paraneoplastic Leukocytosis and Thrombocytosis as Prognostic Biomarkers in Non-small Cell Lung Cancer].

Boddu P, Villlines D, Aklilu M.

Zhongguo Fei Ai Za Zhi. 2016 Nov 20;19(11):725-730. Chinese.

14.

Preoperative lymphocyte count is a favorable prognostic factor of disease-free survival in non-small-cell lung cancer.

Zhang J, Huang SH, Li H, Li Y, Chen XL, Zhang WQ, Chen HG, Gu LJ.

Med Oncol. 2013 Mar;30(1):352. doi: 10.1007/s12032-012-0352-3. Epub 2012 Dec 30.

PMID:
23275140
15.

Prognostic significance of thrombocytosis in patients with primary lung cancer.

Pedersen LM, Milman N.

Eur Respir J. 1996 Sep;9(9):1826-30.

16.

Personalized peptide vaccination in patients with refractory non-small cell lung cancer.

Yoshiyama K, Terazaki Y, Matsueda S, Shichijo S, Noguchi M, Yamada A, Mine T, Ioji T, Itoh K, Shirouzu K, Sasada T, Takamori S.

Int J Oncol. 2012 May;40(5):1492-500. doi: 10.3892/ijo.2012.1351. Epub 2012 Feb 1.

PMID:
22307435
17.

Prognostic role of pretreatment platelet/lymphocyte ratio in patients with non-small cell lung cancer.

Kos M, Hocazade C, Kos FT, Uncu D, Karakas E, Dogan M, Uncu HG, Yildirim N, Zengin N.

Wien Klin Wochenschr. 2016 Sep;128(17-18):635-40. doi: 10.1007/s00508-015-0724-8. Epub 2015 Feb 27.

PMID:
25720573
18.

Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.

Siegfried JM, Weissfeld LA, Singh-Kaw P, Weyant RJ, Testa JR, Landreneau RJ.

Cancer Res. 1997 Feb 1;57(3):433-9.

19.

Expression of HAb18G/CD147 and its localization correlate with the progression and poor prognosis of non-small cell lung cancer.

Xu XY, Lin N, Li YM, Zhi C, Shen H.

Pathol Res Pract. 2013 Jun;209(6):345-52. doi: 10.1016/j.prp.2013.02.015. Epub 2013 Mar 25.

PMID:
23602236
20.

Prognostic significance of the baseline serum uric acid level in non-small cell lung cancer patients treated with first-line chemotherapy: a study of the Turkish Descriptive Oncological Researches Group.

Tanriverdi O, Cokmert S, Oktay E, Pilanci KN, Menekse S, Kocar M, Sen CA, Avci N, Akman T, Ordu C, Goksel G, Meydan N.

Med Oncol. 2014 Oct;31(10):217. doi: 10.1007/s12032-014-0217-z. Epub 2014 Sep 13.

PMID:
25216865

Supplemental Content

Support Center